KR
KRYS.US Krystal Biotech Inc
- Market cap
- USD 9.05B
- P/E
- 41.5x
- P/B
- 6.30x
- ROE
- 16.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KRYS.US undervalued?
Graham numberThe Graham number of Krystal Biotech Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Krystal Biotech Inc fundamental analysis
No fundamental analysis for Krystal Biotech Inc yet.
Krystal Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in…
Full company profileKrystal Biotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Krystal Biotech Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 1.03M | 0.00 | 0.00 | 0.00 | 0.00 | 50.7M | 291M | 389M | 484M |
| Gross Profit | -2.00K | -23.0K | 886K | -974K | -1.85M | -2.77M | -4.06M | 47.6M | 270M | 360M | 457M |
| Operating Income | -1.14M | -4.77M | -11.9M | -22.1M | -33.0M | -68.3M | -145M | -110M | 65.7M | 161M | 244M |
| EBITDA | -1.14M | -4.63M | -10.7M | -18.1M | -30.3M | -65.3M | -116M | -92.2M | 110M | 196M | 284M |
| Net Income | -1.15M | -7.92M | -10.9M | -19.1M | -32.2M | -69.6M | -140M | 10.9M | 89.2M | 205M | 232M |
| EPS | -0.27 | -1.48 | -0.97 | -1.20 | -1.71 | -3.13 | -5.49 | 0.39 | 3.00 | 6.84 | 7.51 |
| Balance Sheet | |||||||||||
| Total Assets | 2.18M | 50.1M | 116M | 209M | 311M | 626M | 558M | 818M | 1.06B | 1.33B | 1.59B |
| Total Liabilities | 1.89M | 640K | 2.89M | 6.11M | 18.8M | 32.7M | 36.2M | 39.7M | 109M | 114M | 150M |
| Shareholders' Equity | 289K | 49.5M | 113M | 203M | 292M | 594M | 522M | 779M | 946M | 1.22B | 1.44B |
| Cash & Short-term Investments | 1.92M | 49.6M | 112M | 194M | 271M | 438M | 379M | 532M | 598M | 828M | 912M |
| Total Debt | 1.84M | - | - | 3.26M | 11.5M | 8.02M | 8.93M | 8.09M | 7.26M | 9.34M | 8.59M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.31M | -3.89M | -9.45M | -18.7M | -26.1M | -47.9M | -101M | -88.8M | 123M | 201M | 329M |
| Capital Expenditure | 15.0K | 210K | 2.23M | 6.40M | 14.8M | 68.3M | 53.0M | 11.8M | 4.24M | 12.0M | 15.6M |
| Free Cash Flow | -1.33M | -4.10M | -11.7M | -25.1M | -40.9M | -116M | -154M | -101M | 119M | 189M | 313M |
| Ratios | |||||||||||
| ROE | -397.9% | -16.0% | -9.6% | -9.4% | -11.0% | -11.7% | -26.8% | 1.4% | 9.4% | 16.8% | 16.1% |
| ROA | -52.7% | -15.8% | -9.4% | -9.1% | -10.3% | -11.1% | -25.1% | 1.3% | 8.4% | 15.4% | 14.6% |
| Net Profit Margin | - | - | -1,060.3% | - | - | - | - | 21.6% | 30.7% | 52.6% | 47.9% |
| Debt to Equity | 6.38x | - | - | 0.02x | 0.04x | 0.01x | 0.02x | 0.01x | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Krystal Biotech Inc dividends
Krystal Biotech Inc has not paid dividends in the last 9 fiscal years.
Who owns Krystal Biotech Inc
- Insiders 10.99%
- Institutions 89.01%
- Public & others 0.00%
- Shares outstanding 29.6M
- Free float 23.7M
Top funds holding KRYS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Select Biotechnology | 1.80M | 6.08% | 0.00% | Aug 2026 |
| iShares Core S&P Mid-Cap ETF | 958K | 3.23% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 848K | 2.86% | -4.85% | Sep 2026 |
| Fidelity Growth Company Fund | 816K | 2.75% | +0.82% | Aug 2026 |
| American Funds SMALLCAP World A | 752K | 2.54% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 661K | 2.23% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 599K | 2.02% | -7.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 455K | 1.54% | +2.68% | Oct 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 334K | 1.13% | -9.70% | Sep 2026 |
| Hood River Small-Cap Growth Instl | 330K | 1.11% | 0.00% | Jun 2026 |
| Fidelity Small Cap Index | 286K | 0.97% | +0.15% | Aug 2026 |
| Invesco S&P MidCap Momentum ETF | 270K | 0.91% | -0.06% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 246K | 0.83% | -0.38% | Oct 2026 |
| Fidelity Growth Company K6 | 229K | 0.77% | +0.09% | Aug 2026 |
| iShares Biotechnology ETF | 202K | 0.68% | -0.36% | Oct 2026 |
| Franklin DynaTech Fund A | 200K | 0.67% | +13.58% | Sep 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 197K | 0.66% | +2.65% | Sep 2026 |
| Fidelity Series Growth Company | 195K | 0.66% | +0.10% | Aug 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 160K | 0.54% | -0.26% | Oct 2026 |
| Vanguard Russell 2000 ETF | 152K | 0.51% | +1.14% | Sep 2026 |
Top institutions holding KRYS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 4.42M | 14.91% | +1.01% | Jun 2026 |
| BlackRock Inc | 4.18M | 14.11% | +6.12% | Jun 2026 |
| venBio Select Advisor LLC | 2.89M | 9.75% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.57M | 5.31% | +8.11% | Jun 2026 |
| State Street Corp | 1.35M | 4.56% | +2.79% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.24M | 4.19% | +6.46% | Jun 2026 |
| Soleus Capital Management, L.P. | 939K | 3.17% | -18.54% | Jun 2026 |
| Capital World Investors | 778K | 2.62% | -5.68% | Jun 2026 |
| Vestor Capital Partners | 701K | 2.37% | +350,357.00% | Jun 2026 |
| Geode Capital Management, LLC | 699K | 2.36% | +8.54% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 687K | 2.32% | +41.71% | Jun 2026 |
| Hood River Capital Management LLC | 663K | 2.24% | +7.07% | Jun 2026 |
| Redmile Group, LLC | 632K | 2.13% | -6.16% | Jun 2026 |
| William Blair Investment Management, LLC | 570K | 1.92% | +40.03% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 481K | 1.62% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 470K | 1.59% | -1.26% | Sep 2026 |
| First Trust Advisors L.P. | 325K | 1.10% | -7.31% | Jun 2026 |
| Amvescap Plc. | 325K | 1.10% | +29.19% | Jun 2026 |
| The Goldman Sachs Group Inc | 299K | 1.01% | +39.03% | Jun 2026 |
| Northern Trust Corp | 284K | 0.96% | +12.41% | Jun 2026 |
Krystal Biotech Inc company profile
- Company name
- Krystal Biotech Inc
- Ticker
- KRYS.US
- Exchange
- USA Stocks
- Listed since
- Sep 20, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 295
- Fiscal year end
- December
- Address
- 2100 Wharton Street, Pittsburgh, PA, United States, 15203
- Phone
- 412 586 5830
- Website
- krystalbio.com
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Krystal Biotech Inc management
10- Mr. Krish S. Krishnan M.B.A., M.S.Founder, Chairman, President & CEO · born 1965
- Ms. Suma M. KrishnanFounder, President of R&D and Director · born 1965
- Ms. Kathryn A. Romano CPAExecutive VP & Chief Accounting Officer · born 1982
- Mr. John C. ThomasEVP, General Counsel & Corporate Secretary · born 1974
- Mr. John KarakkalVice President of North American Sales & Marketing
- Dr. Stephane Paquette Ph.D.Senior Vice President of Corporate Development
- Mr. Josh SuskinSenior Director & Head of US Human Resources
- Mr. Laurent GouxExecutive VP & Head of International · born 1975
- Dr. David Chien M.D.Senior Vice President of Clinical Development
- Ms. Christine WilsonSenior VP & Head of US Commercial